Results 201 to 210 of about 3,326,153 (390)

Myocardium as contributor of plasminogen activator to blood. [PDF]

, 1971
Ipseeta Menon, H. A. Dewar
openalex   +1 more source

Adverse events of tissue plasminogen activators in acute myocardial infarction patients: a real-world and pharmacovigilance database analysis. [PDF]

BMC Cardiovasc Disord
Liu F, Yang G, Xie J, Xie P, Zhou F, Yang F, Ma Y, Xu F.   +7 more
europepmc   +1 more source

Safety and Efficacy of Long‐Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy

Haemophilia, EarlyView.
ABSTRACT Introduction Type 1 plasminogen deficiency (PLGD‐1), or hypoplasminogenaemia, is an ultra‐rare autosomal‐recessive disorder characterised by fibrin‐rich lesions on mucous membranes, often leading to serious complications if left untreated. Prior treatments have shown limited and inconsistent success, but IV PLG concentrate (Ryplazim) offers a ...
Amy D. Shapiro, Heather McDaniel, Robert W. Decker, Charles Nakar, Jeremy Lorber, Neelam Thukral, Joseph M. Parker, Karen Thibaudeau   +7 more
wiley   +1 more source

Plasminogen, the Serum Proenzyme Activated by Factors from Cells Transformed by Oncogenic Viruses

, 1974
James P. Quigley, Liliana Ossowski, E. Reich   +2 more
openalex   +1 more source

Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop. [PDF]

Protein Sci, 2016
Qureshi T, Goswami S, McClintock CS, Ramsey MT, Peterson CB.   +4 more
europepmc   +1 more source

Uniqueness of plasminogen activators [PDF]

Nature, 1976
Judith K. Christman, George Acs
openaire   +3 more sources

Current Practice Regarding Bleeding Disorders of Unknown Cause in the Netherlands: A National Survey

Haemophilia, EarlyView.
ABSTRACT Introduction About 40%–70% of persons with a clinically relevant bleeding tendency who are referred to haemostasis experts are classified as having a ‘bleeding disorder of unknown cause’ (BDUC) as no biological entity can be found after extensive laboratory testing.
Caroline M. A. Mussert, Amaury L. L. Monard, Tirsa T. van Duijl, Yvonne M. C. Henskens, Maartje van den Biggelaar, Roger E. G. Schutgens, Saskia E. M. Schols, Karin J. Fijnvandraat, Karina Meijer, Paul L. den Exter, Laurens Nieuwenhuizen, Iris van Moort, Marieke J. H. A. Kruip, Marjon H. Cnossen, Floor C. J. I. Heubel‐Moenen, for the BDUC‐iN study group   +15 more
wiley   +1 more source

Differences in thrombolytic effects in accordance with dosing- resimens of tissue- type plasminogen activator in experimental pulmonary embolism. [PDF]

, 1970
Hee Soon Chung, Ho Jung Kim, Yong Chol Han   +2 more
openalex   +1 more source

Tissue and urokinase plasminogen activators instigate the degeneration of retinal ganglion cells in a mouse model of glaucoma. [PDF]

Exp Eye Res, 2016
Chintala SK.
europepmc   +1 more source

Unmasking Convergent Inflammatory and Oxidative Pathways in Asthma

Allergy, EarlyView.
Konstantinos Tourlakopoulos, Georgios Mavrovounis, Lamprini Kontopoulou, Spyros Polyzois, Ioannis Pantazopoulos, Paraskevi Kirgou, Zoe Daniil, Konstantinos I. Gourgoulianis, Ourania S. Kotsiou   +8 more
wiley   +1 more source